Covance creates a global immunology and immunotoxicology unit

| By | Drug Development, Laboratories, R&D
0
411

LabCorp, a leading global life sciences company, announced that its Covance Drug Development business has formed a global immunology and immunotoxicology (I&I) unit dedicated to the specific needs of biologic drug development.

This team brings together Covance’s operational expertise in flow cytometry, immunoassays and cell-based assays with its scientific expertise in immunotoxicology study design, direction and operation to provide a more comprehensive offering for large-molecule drugs. Covance’s immunology and immunotoxicology experts support and advise in the development of biologic projects from pre-clinical evaluation to new drug regulatory submission and clinical study sample analysis.

The new I&I unit’s comprehensive offering also includes a seamless bridge to bioanalysis for use in regulatory submissions and to Covance Phase I clinical research units for first-in-human and first-in-patient studies. As studies progress, the I&I team can complete its unique set of solutions by drawing on additional expertise from Covance’s clinical development and commercialization, translational biomarker, immuno-oncology and central laboratory teams, as well as LabCorp’s specialist scientific and technical capabilities.

Covance’s initial investment in I&I capabilities focused on increasing global capacity by expanding dedicated laboratory space, state-of-the-art instrumentation and scientific and operations teams. In 2017 alone, Covance more than doubled its I&I laboratory footprint, including additional space in three locations and establishing a new innovation laboratory for method development and validation.

SOURCE: business wire
SHARE
GMP news
Pharmaceutical industry News and events. Technology transfer and contract manufacturing of medicines.